These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 39056216)
1. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients. Zheng K; Azhie A; You X; Naghibzadeh M; Tan E; Naimimohasses S; Sridhar VS; Gupta S; Chen S; Dash S; Tsien C; Selzner N; Lilly L; Jaeckel E; Woo M; Singh S; Cherney D; Bhat M Diabetes Obes Metab; 2024 Oct; 26(10):4261-4272. PubMed ID: 39056216 [TBL] [Abstract][Full Text] [Related]
2. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE). Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188 [TBL] [Abstract][Full Text] [Related]
3. Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database. Anson M; Henney AE; Zhao SS; Ibarburu GH; Lip GYH; Cuthbertson DJ; Nabrdalik K; Alam U Diabetes Obes Metab; 2024 Jul; 26(7):2606-2623. PubMed ID: 38558280 [TBL] [Abstract][Full Text] [Related]
4. Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis. Zafar Y; Rashid AM; Siddiqi AK; Ellahi A; Ahmed A; Hussain HU; Ahmed F; Menezes RG; Siddiqi TJ; Maniya MT Clin Res Hepatol Gastroenterol; 2022; 46(7):101970. PubMed ID: 35659603 [TBL] [Abstract][Full Text] [Related]
5. Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review. Chai S; Niu Y; Liu F; Wu S; Yang Z; Sun F J Diabetes Res; 2024; 2024():8145388. PubMed ID: 39072050 [No Abstract] [Full Text] [Related]
6. Influence of early use of sodium-glucose transport protein 2 inhibitors, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on the legacy effect of hyperglycemia. Deng S; Zhao H; Chai S; Sun Y; Shen P; Lin H; Zhan S Front Endocrinol (Lausanne); 2024; 15():1369908. PubMed ID: 38803473 [TBL] [Abstract][Full Text] [Related]
8. SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes. Zhuo M; Paik JM; Wexler DJ; Bonventre JV; Kim SC; Patorno E Am J Kidney Dis; 2022 Jun; 79(6):858-867.e1. PubMed ID: 34762974 [TBL] [Abstract][Full Text] [Related]
9. Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study. Bea S; Son H; Bae JH; Cho SW; Shin JY; Cho YM Diabetes Obes Metab; 2024 Jan; 26(1):108-117. PubMed ID: 37735822 [TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta-analysis. Cao H; Liu T; Wang L; Ji Q Diabetes Obes Metab; 2022 Aug; 24(8):1448-1457. PubMed ID: 35665989 [TBL] [Abstract][Full Text] [Related]
11. Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints. Patoulias D; Katsimardou A; Kalogirou MS; Zografou I; Toumpourleka M; Imprialos K; Stavropoulos K; Stergiou I; Papadopoulos C; Doumas M Diabetes Metab; 2020 Sep; 46(4):272-279. PubMed ID: 32437914 [TBL] [Abstract][Full Text] [Related]
12. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials. Tran S; Retnakaran R; Zinman B; Kramer CK Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():68-76. PubMed ID: 29364587 [TBL] [Abstract][Full Text] [Related]
14. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials. Lee MMY; Petrie MC; McMurray JJV; Sattar N Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025 [TBL] [Abstract][Full Text] [Related]
15. SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study. Fu EL; Wexler DJ; Cromer SJ; Bykov K; Paik JM; Patorno E BMJ; 2024 Jun; 385():e078483. PubMed ID: 38925801 [TBL] [Abstract][Full Text] [Related]
16. Glycaemic control and macrovascular and microvascular outcomes in type 2 diabetes: Systematic review and meta-analysis of cardiovascular outcome trials of novel glucose-lowering agents. Kunutsor SK; Zaccardi F; Balasubramanian VG; Gillies CL; Aroda VR; Seidu S; Davies MJ; Khunti K Diabetes Obes Metab; 2024 May; 26(5):1837-1849. PubMed ID: 38379094 [TBL] [Abstract][Full Text] [Related]
17. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus. Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326 [TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase 4 inhibitors, sodium glucose cotransporter 2 inhibitors, and glucagon-like peptide 1 receptor agonists do not worsen diabetic macular edema. Phu A; Banghart M; Bahrainian M; Liu TYA; Wolf RM; Channa R J Diabetes Complications; 2024 Aug; 38(8):108808. PubMed ID: 39018897 [TBL] [Abstract][Full Text] [Related]
19. Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury. Zhao M; Sun S; Huang Z; Wang T; Tang H Clin J Am Soc Nephrol; 2020 Dec; 16(1):70-78. PubMed ID: 33376101 [TBL] [Abstract][Full Text] [Related]
20. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]